US EditionPublished • loading... • Updated
Eli Lilly Becomes First Trillion-Dollar Health Company
- On Nov. 21, Eli Lilly reached a $1 trillion market valuation in trading Friday, briefly crossing the threshold before its stock pulled back in U.S. stock markets.
- Lilly's surge follows sales of Mounjaro and Zepbound, which generated $11.54 billion and $4.93 billion by 2024, while shares rose more than 36% this year.
- After winning approvals, Lilly now faces intensified competition as Pfizer paid $10 billion for Metsera earlier this month and two new injectable obesity drugs enter trials.
- Some analysts predict the market could exceed $150 billion by the early 2030s, and Eli Lilly expects continued growth as insurance and approvals expand access with an oral version next year.
- As a rare non-tech trillion-dollar firm, Eli Lilly is the first healthcare company to reach $1 trillion and only the second after Warren Buffett's Berkshire Hathaway, founded in 1876 with milestones like 1923's insulin and Prozac.
Insights by Ground AI
34 Articles
34 Articles
Coverage Details
Total News Sources34
Leaning Left7Leaning Right3Center8Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 39%
C 44%
R 17%
Factuality
To view factuality data please Upgrade to Premium
